Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $20.83.

ALT has been the subject of a number of recent research reports. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. Finally, Stifel Nicolaus initiated coverage on shares of Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company.

Insider Buying and Selling

In other news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.10% of the stock is owned by insiders.

Institutional Trading of Altimmune

A number of hedge funds have recently modified their holdings of the business. Barclays PLC lifted its position in Altimmune by 1.1% during the 4th quarter. Barclays PLC now owns 157,528 shares of the company’s stock valued at $1,135,000 after acquiring an additional 1,787 shares during the period. Rafferty Asset Management LLC boosted its position in shares of Altimmune by 1.3% in the 4th quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company’s stock worth $1,137,000 after purchasing an additional 1,964 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Altimmune by 2.0% in the 4th quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company’s stock worth $742,000 after buying an additional 2,028 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its position in Altimmune by 12.9% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after buying an additional 2,687 shares in the last quarter. Finally, MetLife Investment Management LLC raised its stake in Altimmune by 7.0% during the fourth quarter. MetLife Investment Management LLC now owns 44,474 shares of the company’s stock valued at $321,000 after buying an additional 2,897 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Altimmune Price Performance

NASDAQ:ALT opened at $4.97 on Thursday. The company has a market capitalization of $382.68 million, a price-to-earnings ratio of -3.21 and a beta of 0.91. The business has a 50 day moving average of $5.32 and a 200 day moving average of $6.70. Altimmune has a 1-year low of $3.55 and a 1-year high of $11.16.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. As a group, sell-side analysts anticipate that Altimmune will post -1.35 EPS for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.